Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adamantane SCHEMBL3322185 | 0.81 | KMT2A (0.72) | LMNAKMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL3322052 | 0.80 | KMT2A (0.74) | LMNAKMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL3320998 | 0.73 | HPGD (0.75) | LMNAKMT2AMEN1HSD11B1EPHX2 | |
| SCHEMBL3322179 | 0.69 | LMNA (0.63) | LMNAKMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL3320032 | 0.67 | KMT2A (0.74) | LMNAKMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL2730689 | 0.65 | SMN1; SMN2 (0.85) | LMNAKMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL12326826 | 0.64 | KMT2A (0.62) | LMNAKMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL660986 | 0.64 | KMT2A (0.62) | LMNAKMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL13932527 | 0.64 | KMT2A (0.83) | LMNAKMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL18088397 | 0.64 | HDAC6 (0.61) | LMNAKMT2AMEN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | LMNA 4234/4885KMT2A 3083/4885MEN1 3474/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | LMNA 4234/4885KMT2A 2533/4885MEN1 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.